Sequence Listing Requirements in European Divisional Patent Applications
For biotech, pharma and life sciences applicants, filing a divisional application at the European Patent Office involves an extra layer of complexity that most other technology fields never encounter: the sequence listing. Since the 2022 transition to WIPO Standard ST.26, sequence listings for divisionals have become a genuine trap for the unwary – capable of […]
Transgenic Animal Patents: Sequence Listing Requirements for Genetically Modified Organisms
Patenting genetically modified animals presents a unique combination of biotechnology, patent drafting and regulatory challenges. In applications involving transgenic animals, the genetic construct may be central to the invention, while nucleotide and amino acid sequences can provide the technical detail needed to define the modification with precision. For patent applicants, however, describing a genetic sequence […]
IPO India Sequence Listing Requirements for Biotech Patent Applications
Biotechnology patent applications often contain nucleotide, amino acid, peptide, DNA, RNA, or other biological sequence information. Because these sequences can be central to the invention – and can be difficult to search and examine – the Indian Patent Office (IPO India) requires sequence disclosures to be submitted in a prescribed electronic format. For applications filed […]
Using Sequence Listings as a Competitive Intelligence Tool in Biotech
In biotechnology, patents are more than legal documents. They can also provide a detailed window into a competitor’s research priorities, technical capabilities and product-development strategy. One of the most valuable – and sometimes verlooked – sources of intelligence within a biotech patent portfolio is the sequence listing. Sequence listings disclose nucleotide and amino-acid sequences associated with […]
Zero Trust Cybersecurity Patent Invalidity: NIST Framework and IETF RFC Prior Art
Zero trust has become a central architecture for modern cybersecurity, with concepts such as continuous authentication, identity-based access control, device verification, least-privilege access, micro-segmentation and resource-level protection appearing throughout the technical literature. For patent attorneys evaluating cybersecurity patents, these concepts can also create a substantial prior-art landscape. NIST publications and IETF RFCs can be particularly valuable […]
Epigenetics Patent Applications: When and How to Include Sequence Listings
Epigenetics research is producing increasingly valuable inventions involving DNA methylation, histone modification, chromatin regulation, gene-expression control, epigenetic biomarkers, and therapeutic technologies. As these discoveries move from the laboratory into patent applications, one technical issue deserves particular attention: when and how biological sequence information must be presented in a sequence listing. For patent applications containing qualifying nucleotide […]
Sequence Listing Analysis in Freedom-to-Operate (FTO) Studies
For companies working in biotechnology, pharmaceuticals, diagnostics, agriculture and other life-science fields, freedom-to-operate (FTO) analysis is an important part of intellectual property risk management. Before investing heavily in the development or commercialization of a biological product, businesses need to understand whether third-party patent rights could restrict their activities. When an invention involves DNA, RNA, proteins, peptides, antibodies, […]
Sequence Listing Analysis in Freedom-to-Operate (FTO) Studies
For companies working in biotechnology, pharmaceuticals, diagnostics, agriculture and other life-science fields, freedom-to-operate (FTO) analysis is an important part of intellectual property risk management. Before investing heavily in the development or commercialization of a biological product, businesses need to understand whether third-party patent rights could restrict their activities. When an invention involves DNA, RNA, proteins, peptides, antibodies, […]
Cancer Immunotherapy Patents: Sequence Listing Preparation for Complex Biologics
Cancer immunotherapy patents often involve some of the most sequence-intensive technologies in biotechnology. Antibodies, antibody fragments, T-cell receptors, chimeric antigen receptors, cytokines, fusion proteins, nucleic acid constructs, engineered binding proteins, and other biologics can generate hundreds or even thousands of nucleotide and amino acid sequences across a single patent family. For these applications, sequence-listing preparation […]
Zinc Finger Nuclease and TALEN Patent Filings: Sequence Listing Requirements
Introduction Patent applications directed to zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) routinely contain substantial nucleotide and amino acid sequence information. That creates a practical filing issue that is easy to underestimate: when does a sequence need to appear in the patent’s formal sequence listing and how should it be prepared? For […]